

DRUG PRIOR AUTHORIZATION COMMITTEE MEETING
December 20, 2018
Missouri Coalition for Community Behavioral Healthcare,
Lower Level CEO Room,
Jefferson City, MO

Committee Members Present

Conrad Balcer, D.O., Chair
Laura Kingsley, Pharm D
Laine Young-Walker, MD
Pat Bryant, Pharm D
Morgan Sperry, alternate

MO HealthNet Staff Present:

Mark Roaseau, R.Ph, Clinical Pharmacist
Sharie Hahn, Special Counsel
Jessica Veit, RN, Clinical Management
Angela Wilson, Pharmacy Operations Manager
Beth Mitchell, Administrative Office Support Assistant
Mitch Ruth, Pharmacy Fiscal Unit Manager
Dr. Timothy Kling, MD, Assistant Medical Director
Lisa E. Smith, Program Development Specialist
Jackie Hickman, Drug Rebate Unit Supervisor
Jackie Hickman, Drug Rebate Supervisor
Kari Ballew, Drug Rebate Unit Medicaid Specialist
Elizabeth Short, Program Specialist

Contractors in Attendance:

Joshua Moore, Pharm D, Conduent
Luke Boehmer, Pharm D, Conduent

Katie Wilbers, Pharm D, Conduent
Janelle Sheen, Pharm D, Conduent
Olivia Rush, Pharm D, Conduent
Geri Roling, Wipro
Chelsea Pendleton, Wipro

Others Attending:

Laura Hill, AbbVie
Michael Lafond, Abbvie
Zac Henney, AkaRx, Inc.
Evan Rushing, Alkermes
Audrey Rattan, Alkermes
Dr. Shelly Thompson, Alkermes
Kristi Kemp, Allergan
Andrew Kucharski, Alnylam
Matthew Stroh, Astra Zeneca
Kin Wine, Avexis
Robert Kilo, Biogen
Aaron Shaw, Boehringer Ingelehim
Chi Kohuhoff, Braeburn
Matthew Mage, Braeburn
Katrina McDonald, Compass
Zack Henney, Dova
Garth Wright, Genentech
Brian Striekland, Giland
Robert Robey, Indivior
Christy Skibicki, Indivior
Joan Houska, J&J
Erin Hohman, Janssen

Jennifer Stoffel, Janssen
Mary Stewart Nelson, Janssen
Jennifer Davis, Kite Pharma
Jeff Eskew, Kite Pharma
Tom Guyer, Lilly
Mark Forkner, Lundbeck
Tobey, Houmbrecker, Merck
Kim Moore, MPA/GLO
Kathi Harness, MHA, Eastern MO
Gena Terlizzi, NAMI
Evie Kniseley, Novartis
Matt Bradley, Novartis
Gerri Lynn Utter, Orexo
Lisa Gilliam, Orexo
Rick Kegler, Otsuka
Charlie Kelley, Pharming
Scott Symes, Pharming Healthcare
Jim Baumann, Pfizer
Phil King, Pfizer
Chet Stukk, Purdue
Steven Woods, Relypsa
PJ Arnold, Shire
Nike Holmes, Sunnovion
Michael Nelson, Sunnovion
Heather Maruska, UHC
Eric Gaudner, Vertex
Doug Wood, Viiv
Denise Mills, advocate

Welcome, Introductions and Opening Remarks	Conrad Balcer, Chair, called the meeting to order. Mark Roaseau introduced himself and started the introductions and opening remarks.
Minutes Approval	Minutes of the September 2018 Drug PA meeting were reviewed and approved. Pat Bryant made the motion and Laura Kingsley seconded the motion.
Pharmacy Program/Budget Update	Mitch Ruth presented a brief power point. The presentation contained graphs representing demographic information about MHD participants, drug expenditures by participant groups, drug class, and program. Information was also provided on selected drug expenditures and initiatives MHD is tracking.
Old Business	
Old Business Implementation Schedule	An updated copy of the Proposed Implementation Schedule for Edits, including PDL classes was included in the Members' meeting packet and provided as a handout to all attending. The Schedule included June/July, 2018 PDL decisions to be implemented October 4, 2018. Pending ratification, PDL decisions from the September 2018 Drug PA Committee meeting will be implemented January 2019. Schedules may be found on the MHD web page at
	https://dss.mo.gov/mhd/cs/pharmacy/pdf/impsched.pdf

New Business	
New Drug Review	<p>Mark Roaseau reviewed the new products identified for the quarter July, August and September, 2018 and the recommended status within the clinical program.</p> <ul style="list-style-type: none"> ● Discussion – A listing of products recommended for open access, clinical edit, preferred drug list (PDL) product, or continued prior authorization was provided in the Members’ meeting packet for discussion and action. This listing was also provided as a handout to all attending. ● Public Hearing – Zac Henney represented AkaRx, Inc. commented on Doptelet, Laura Hill represented AbbVie commented on Humira, Orlissa. Andrew Kucharski, PHD represented Alnylam Pharmaceuticals commented on Onpattro ● Decision – Members voted to accept the new product recommendations as presented
Clinical Edits	
Orlissa Clinical Edit	<ul style="list-style-type: none"> ● Discussion – Mr. Roaseau reviewed the new criteria in this document. ● Public Hearing – Laura Hill represented AbbVie commented on Orlissa. ● Decision – The Committee voted to accept this Clinical Edit as presented. (See Roll Call Vote)
Galafold Clinical Edit	<ul style="list-style-type: none"> ● Discussion – Mr. Roaseau reviewed the new criteria in this document. ● Public Hearing – No comments entered ● Decision – The Committee voted to accept this Clinical Edit as presented. (See Roll Call Vote)
Onpattro Clinical Edit	<ul style="list-style-type: none"> ● Discussion – Mr. Roaseau reviewed the new criteria in this document. ● Public Hearing – Andrew Kucharski commented on Onpattro. ● Decision – The Committee voted to accept this Clinical Edit as presented. (See Roll Call Vote)

Preferred Drug List (PDL)	
Alzheimer's Agents	<ul style="list-style-type: none"> • Discussion – Mr. Roaseau reviewed the criteria document, reviewing preferred. • Public Hearing – No Comments Entered • Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Antiemetic 5-HT3 and Other Agents	<ul style="list-style-type: none"> • Discussion – Mr. Roaseau reviewed the criteria document, reviewing preferred and non-preferred agents. • Public Hearing – No comments entered. • Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Antiemetic, Substance P/Neurokinin1 (NK1) Receptor Agonist Agents	<ul style="list-style-type: none"> • Discussion – Mr. Roaseau reviewed the criteria document, reviewing preferred and non-preferred agents. • Public Hearing – Justin Barnes represented Trsipharma commented on Dynavael XR. • Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Antiemetic, THC Derivative Agents	<ul style="list-style-type: none"> • Discussion – Mr. Roaseau stated there are no changes recommended for this class. • Public Hearing – No comments entered. • Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Anti-Migraine, Serotonin (5-HT1) Receptor Agents blocker Combination Agents	<ul style="list-style-type: none"> • Discussion – Mr. Roaseau stated there are no changes recommended for this class. • Public Hearing – No comments entered. • Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)

Antipsychotics-2nd Generation (Atypical) Reference Product List (New)	<ul style="list-style-type: none"> ● Discussion – Mr. Roaseau reviewed the criteria document, reviewing preferred and non-preferred agents. ● Public Hearing – Christy Skibicki, MD represented Perseris, Erin Hohman represented Invega Sustenna/Invega Trainza, Gena Terlizza, NAMI shared personal experience, Dr. Shelly Thompson represented Aristada and Aristada Intitio, Rick Kegler represented Abilify maintena and Rexulti. ● Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Cox-II Inhibitor Agents	<ul style="list-style-type: none"> ● Discussion – Mr. Roaseau reviewed the criteria document, reviewing preferred and non-preferred agents. ● Public Hearing – No comments entered. ● Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Electrolyte Depleters, Potassium Lowering Agents (New)	<ul style="list-style-type: none"> ● Discussion – Mr. Roaseau reviewed the criteria document, reviewing preferred and non-preferred agents. ● Public Hearing – No comments entered. ● Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Fibromyalgia Agents	<ul style="list-style-type: none"> ● Discussion – Mr. Roaseau stated there are no changes recommended for this class. ● Public Hearing – No comments entered. ● Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)

Hereditary Angioedema Treating Agents (NEW)	<ul style="list-style-type: none"> • Discussion – Mr. Roaseau stated there are no changes recommended for this class. • Public Hearing – Charlie Kelly represented Pharma, Phil Arnold represented Shire • Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
IBS, Anti-Diarrheal Agents	<ul style="list-style-type: none"> • Discussion – Mr. Roaseau reviewed the criteria document, reviewing preferred and non-preferred agents. • Public Hearing – No Comments were entered. • Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
IBS-C/CIC Agents	<ul style="list-style-type: none"> • Discussion – Mr. Roaseau stated there are no changes recommended for this class. • Public Hearing – No comments were entered. • Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Neuropathic Pain Agents	<ul style="list-style-type: none"> • Discussion – Mr. Roaseau stated there are no changes recommended for this class. • Public Hearing – No comments were entered. • Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Non-Ergot Dopamine Receptor Agonist Agents	<ul style="list-style-type: none"> • Discussion – Mr. Roaseau reviewed the criteria document, reviewing preferred and non-preferred agents. • Public Hearing – No comments were entered. • Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)

NSAID Agents	<ul style="list-style-type: none"> • Discussion – Mr. Roaseau stated there are no changes recommended for this class. • Public Hearing – No comments were entered. • Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Opioid Dependence Agents	<ul style="list-style-type: none"> • Discussion – Mr. Roaseau stated there are no changes recommended for this class. • Public Hearing – Dr. Shelly Thompson represented Alkermes, Inc., Christy Skibicki, MD represented Indivior, Gerri Lynn Gothrie represented Orexo. Letter from American Society of Addiction Medicine and letter from Representative Holly Rehder • Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Opioid Emergency Reversal Agents	<ul style="list-style-type: none"> • Discussion – Mr. Roaseau reviewed the criteria document, reviewing preferred and non-preferred agents. • Public Hearing – No comments were entered. • Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Opioid, Long-Acting Agents	<p>Discussion – Mr. Roaseau stated there are no changes recommended for this class.</p> <p>Public Hearing – No comments were entered.</p> <p>Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</p>
Sedative-Hypnotic Agents	<ul style="list-style-type: none"> • Discussion – Mr. Roaseau reviewed the criteria document, reviewing preferred and non-preferred agents. • Public Hearing – No comments were entered. • Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)

Skeletal Muscle Relaxant Agents	<ul style="list-style-type: none"> • Discussion – Mr. Roaseau reviewed the criteria document, reviewing preferred and non-preferred agents. • Public Hearing – No comments were entered. • Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Thrombocytopenia Treating Agents (NEW)	<p>Discussion – Mr. Roaseau reviewed the criteria document, reviewing preferred and non-preferred agents.</p> <ul style="list-style-type: none"> • Public Hearing – No comments were entered. • Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Tramadol-Like Agents	<ul style="list-style-type: none"> • Discussion – Mr. Roaseau reviewed the criteria document, reviewing preferred and non-preferred agents. • Public Hearing – No comments were entered. • Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Preferred Drug List Announcement	<p>A handout of therapeutic categories to be reviewed for inclusion on the Preferred Drug List for the next phase and meeting was included in the meeting packet. This handout was also provided to all attendees and will be posted to the Division's web page:</p>
	<p>http://dss.mo.gov/mhd/cs/pharmacy/pdf/pdla.pdf</p>
Conduent Update	<p>Conduent did present the following items for review. These items were included in the packet for the meeting. Here is the list:</p> <ul style="list-style-type: none"> • Call Center Statistics, Claims, Spend, and Diagnosis information for the SSRI's and SNRI's. • New Drug Summary.

Program Utilization: Top 25 Drugs Summary	The Top 25 Drugs Summary Reports for the 3 rd , & 4th quarter of fiscal year 2018 and 1 st and 2 nd quarters for Fiscal year 2019 were provided in the packets for review. Two versions were provided: one report ranked drug spend by dollars and the other by utilization/claims.
Call Center Statistics/MO User Stats/PDL Website-New PDL Listing and Searchable Database Manual	In the packets provided for the meeting were the following handouts and reports: <ul style="list-style-type: none"> • A handout detailing pharmacy help desk call center activity. • MO User Stats • Reports were also provided detailing the number and type of prescribers and active users on Cyber Access. • Preferred Drug List Searchable Database and Static Document Manual
Adjourn	The meeting was adjourned pursuant to Section 610.021 Subsection (14), (5) RSMo for proceedings required pursuant to a disciplinary order concerning medical, psychiatric, psychological, or alcoholism or drug dependency diagnosis or treatment of specific licensees. (See attached roll call) The next meeting of the Drug Prior Authorization Committee is scheduled for March 21, 2019 at the Missouri Coalition for Community Behavioral Healthcare Building, Lower Level CEO Room, 221 Metro Drive, Jefferson City, MO.

Roll Call for December 20, 2018

<u>Member</u>	Minutes	New Drugs	Orlissa	Galafold	Onpattro	Alzheimer's Agents	Antiemetic 5-HT3 and Other Agents	Antiemetic, Substance P/Neurokinin (NK1) Receptor Agonist Agents
Conrad Balcer, D.O.	Y	Y	Y	Y	Y	Y	Y	Y
Pat Bryant, Pharm D	M Y	MY	S Y	Y	Y	MY	SY	SY
Laine Young-Walker, M.D.	Y	Y	M Y	S Y	M Y	Y	Y	MY
Morgan Sperry, Pharm D-Alternate								
Jennifer Kemp-Oestreich, Pharm D	A	A	A	A	A	A	A	A
Laura Kingsley, Pharm D	SY	SY	Y	MY	SY	SY	MY	Y

<u>Member</u>	Antiemetic, THC Derivative Agents	Anti- Migraine, Serotonin (5-HT1) Receptor Agents	Anti- Parkinsonism MAOI-B Agents (New)	Anti-Psychotics-2 nd Generation (Atypical) Reference Product List (New)	Cox-II Inhibitor Agents	Electrolyte Depleters, Potassium Lowering Agents (New)	Fibromyalgia Agents	Hereditary Angioedema Treating Agents (New)
Conrad Balcer, D.O.	Y	Y	Y	Y	Y	Y	Y	Y
Pat Bryant, Pharm D	MY	SY	Y	SY	MY	Y	Y	Y
Laine Young-Walker, M.D.	Y	MY	MY	MY	Y	SY	MY	SY
Morgan Sperry, Pharm D- Alternate								
Jennifer Kemp-Oestreich, Pharm D	A	A	A	A	A	A	A	A
Laura Kingsley, Pharm D	SY	Y	SY	Y	SY	MY	SY	MY

<u>Member</u>	IBS, Anti- Diarrheal Agents	IBS-C/CIC Agents	Neuropathic Pain Agents	Non-Ergot Dopamine Receptor Agonist Agents	NSAID Agents	Opioid Dependence Agents	Opioid Emergency Reversal Agents	Opioids Induced Constipation Agents
Conrad Balcer, D.O.	Y	Y	Y	Y	Y	Y	Y	Y
Pat Bryant, Pharm D	SY	SY	SY	Y	SY	MY	MY	MY
Laine Young-Walker, M.D.	MY	Y	MY	MY	Y	Y	Y	Y
Morgan Sperry, Pharm D- Alternate								
Jennifer Kemp-Oestreich, Pharm D	A	A	A	A	A	A	A	A
Laura Kingsley, Pharm D	Y	MY	Y	SY	SY	SY	SY	SY

<u>Member</u>	Opioids, Long- Acting Agents	Sedative- Hypnotic Agents	Skeletal Muscle Relaxant Agents	Thrombocytopenia Treating Agents (New)	Tramadol- Like Agents	Meeting adjourn
Conrad Balcer, D.O.	Y	Y	Y	Y	Y	Y
Pat Bryant, Pharm D	SY	SY	MY	Y	MY	MY
Laine Young-Walker, M.D.	MY	Y	Y	MY	y	Y
Morgan Sperry, Pharm D- Alternate						
Jennifer Kemp-Oestreich, Pharm D	A	A	A	A	A	A
Laura Kingsley, Pharm D	Y	MY	SY	SY	SY	SY

Roll Call Abbreviations:

A-Absent

AL-Alternate

R-Ratify

M-Motion

S-Second